Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice
HM Salim, D Fukuda, Y Higashikuni, K Tanaka… - Vascular …, 2016 - Elsevier
Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors have vasoprotective effects.
This study investigated whether a recently approved DPP-4 inhibitor, linagliptin (Lina),
suppresses atherogenesis in non-diabetic apolipoprotein-E deficient (ApoE−/−) mice, and
examined its effects on endothelial function. Methods and results Lina (10 mg/kg/day) was
administered orally to ApoE−/− mice for 20 weeks. Lina reduced atherogenesis without
alteration of metabolic parameters including blood glucose level compared with control (P< …
This study investigated whether a recently approved DPP-4 inhibitor, linagliptin (Lina),
suppresses atherogenesis in non-diabetic apolipoprotein-E deficient (ApoE−/−) mice, and
examined its effects on endothelial function. Methods and results Lina (10 mg/kg/day) was
administered orally to ApoE−/− mice for 20 weeks. Lina reduced atherogenesis without
alteration of metabolic parameters including blood glucose level compared with control (P< …